Gabriel Brand, AMFT, APCC Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 10372 W Briar Oaks Dr Apt C, Stanton, CA 90680 Phone: 310-971-5133 |
Summer Nicole Hulsey Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 10862 Oak St, Stanton, CA 90680 Phone: 949-273-0555 |
Daisy Juarez Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 11822 Santa Paula St, Stanton, CA 90680 Phone: 714-379-0129 |
Ms. Vivianne Shands Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 11822 Santa Paula St, Stanton, CA 90680 Phone: 619-823-9772 |
Ms. Dawn Marie Masick, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 7601 Katella Ave Apt 21, Stanton, CA 90680 Phone: 714-855-9002 |
News Archive
Allos Therapeutics, Inc. today announced topline results from the Company's randomized Phase 2b investigational trial of FOLOTYN® (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) who had received one or two prior systemic treatments including at least one prior platinum-based regimen. The objective of the trial was to estimate the efficacy of FOLOTYN compared to that of erlotinib as assessed by overall survival.
QIAGEN N.V. recognized the annual World TB Day 2019 held on March 24 by highlighting its growing global commitment to preventive screening and treatment for latent tuberculosis (TB) infection, a widespread condition that can lead to active TB disease in vulnerable patients.
The presence of myopia, or nearsightedness, significantly affects the muscles used in focusing the lens of the eye-a finding with important implications for the development of "accommodating" implanted intraocular lenses (IOLs) that can adjust to different visual distances, reports a study in the January issue of Optometry and Vision Science, official journal of the American Academy of Optometry.
China Biologic Products, Inc., one of the leading plasma-based biopharmaceutical companies in the People's Republic of China, today announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd., recently received approval from the China State Food and Drug Administration to begin clinical trials for its human fibrinogen to be used to treat congenital fibrinogen deficiency and acquired fibrinogen deficiency.
› Verified 6 days ago